Capsaicin inhibits the in vitro binding of peptides selective for μ- and κ-opioid, and nociceptin-receptors

Brain Research Bulletin

Volumn 77, Issue 2-3, 2008, Pages 136-142

  Wollemann, Mária ^a   Ioja, Eniko ^a   Benyhe, Sándor ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

CHO cells; G protein activation; Interaction; Opioid receptor; Radioligand binding; Rat brain; Vanilloid receptor

Indexed keywords

CAPSAICIN; DYNORPHIN A; ENDOMORPHIN 1; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); KAPPA OPIATE RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; NOCICEPTIN; NOCICEPTIN RECEPTOR; OPIATE PEPTIDE; SULFUR 35; TRITIUM; VANILLOID RECEPTOR 1;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BRAIN MEMBRANE; CHO CELL; CONTROLLED STUDY; IN VITRO STUDY; INHIBITION KINETICS; ISOTOPE LABELING; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOASSAY; RAT; RECEPTOR BINDING;

ANALGESICS, OPIOID; ANIMALS; BRAIN; CAPSAICIN; CHO CELLS; CRICETINAE; CRICETULUS; DYNORPHINS; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; HUMANS; LIGANDS; OLIGOPEPTIDES; OPIOID PEPTIDES; PEPTIDES; PROTEIN BINDING; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, OPIOID; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; SENSORY SYSTEM AGENTS; TRITIUM;

EID: 50949112393     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2008.06.003     Document Type: Article

References (58)

1. Bailey C.P., Smith F.L., Kelly E., Dewey W.L., and Henderson G. How important is protein kinase C in mu-opioid receptor desensitization and morphine tolerance. Trends Pharm. Sci. 27 (2006) 559-564
2. Barrett A.C., Smith E.S., and Picker M.J. Capsaicin-induced hyperalgesia and mu-opioid-induced antihyperalgesia in male and female Fisher 344 rats. J. Pharm. Exp. Ther. 307 (2003) 237-245
3. Bautista D.M., Jordt S.E., Nikai T., Tsuruda P.R., Read A.J., Poblete J., Yamoah E.N., Basbaum A.I., and Julius D. TRPA mediates the inflammatory actions of environmental irritants and proalgesic agents. Cell 124 (2006) 1269-1282
4. Beedle A.M., McRory J.E., Poirot O., Doering C.J., Altier C., Barrere C., Hamid J., Nargeot J., Bourinet E., and Zamponi G.W. Agonist-independent modulation of N-type calcium channels by ORL1 receptors. Nat. Neurosci. 7 (2004) 118-125
5. Benninger F., Freund T.F., and Hájos N. Control of excitatory synaptic transmission by capsaicin is unaltered in TRPV1 vanilloid receptor knockout mice. Neurochem. Int. 52 (2008) 89-94
6. 7, an endogenous neuropeptide, binds to multiple opioid and nonopioid sites in rat brain. J. Neurosci. Res. 48 (1997) 249-258
7. Bevan S., and Szolcsányi J. Sensory neuron-specific actions of capsaicin: mechanism and application. Trends Pharm. Sci. 11 (1990) 330-333
8. Butelman E.R., Harris T.J., and Kreek M.J. Antiallodynic effects of loperamide and fentanyl against topical capsaicin-induced allodynia in unanesthetized primates. J. Pharm. Exp. Ther. 311 (2004) 155-163
9. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., and Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389 (1997) 816-824
10. Chakrabarti S., Liu N.J., and Gintzler A.R. Reciprocal modulation of phospholipase Cβ isoforms: adaptation to chronic morphine. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 13686-13691
11. Corboz M.R., Fernandez X., Egan R.W., and Hey J.A. Inhibitory activity of nociceptin/orphanin FQ on capsaicin-induced bronchoconstriction in the guinea pig. Life Sci. 69 (2001) 1203-1211
12. Cui M., Honore P., Zhong C., Gauvin D., Mikusa J., Hernandez G., et al. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists. J. Neurosci. 26 (2006) 9385-9393
13. De Petrocellis L., Harrison S., Bisogno T., Tognetto M., Brandi I., Smith G.D., Creminon C., Davis J.B., Geppetti P., and Di Marzo V. The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase. J. Neurochem. 77 (2001) 1660-1663
14. Dubner R., and Ruda M.A. Activity-dependent neuronal plasticity following tissue injury and inflammation. Trends Neurosci. 15 (1992) 96-103
15. Goldstein A., Fischli W., Lowney L.I., Hunkapiller M., and Hood L. Porcine pituitary dynorphin: complete amino acid sequence of the biological active heptadecapeptide. Proc. Natl. Acad. Sci. U.S.A. 78 (1981) 7219-7223
16. O. Gunduz, E. Baldini, A. Borsodi, S. Benyhe, M. Corbani, Investigation of mu-opioid receptor (MOP) and nociceptin/orphanin FQ peptide receptor (NOP) heterodimerization, International Narcotics Research Conference, Berlin, Abstracts, 2007, p. 43.
17. Gunthorpe M.J., Benham C.D., Randall A., and Davis J.B. The diversity in the vanilloid (TRPV) receptor family of ion channels. Trends Pharm. Sci. 23 (2002) 183-191
18. Hannan M.A., Kabbani N., Paspalas C.D., and Levenson R. Interaction with dopamine D2 receptor enhances expression of transient receptor potential channel 1 at the cell surface. Biochim. Biophys. Acta 1778 (2008) 974-982
19. Jancsó G., and Jancsó-Gábor A. Effect of capsaicin on morphine analgesia-possible involvement of hypothalamic structures. Naunyn Schmiedeberg's Arch. Pharmacol. 311 (1980) 285-288
20. Kelly E., Bailey C.P., and Henderson G. Agonist-selective mechanisms of GPCR desensitization. Br. J. Pharmacol. 153 Suppl. 1 (2008) S379-388
21. Kieffer B.L. Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. Cell. Mol. Neurobiol. 15 (1995) 615-635
22. Ko M.C.H., Butelman E.R., and Woods J.H. The role of peripheral mu opioid receptors in the modulation of capsaicin-induced thermal nociception in Rhesus monkeys. J. Pharm. Exp. Ther. 286 (1998) 150-156
23. Ko M.C.H., Johnson M.D., Butelman E.R., Willmont K.J., Mosberg H.I., and Woods J.H. Intracisternal nor-binaltorphimine distinguishes central and peripheral kappa-opioid antinociception in Rhesus monkeys. J. Pharm. Exp. Ther. 291 (1999) 1113-1120
24. Ko M.C.H., Willmont K.J., Burritt A., Hruby V.J., and Woods J.H. Local inhibitory effects of dynorphin-A-(1-17) on capsaicin-induced thermal allodynia in Rhesus monkeys. Eur. J. Pharm. 402 (2000) 69-76
25. Kocsis L., Orosz G., Magyar A., Al-Khrasani M., Kato E., Rónai A.Z., Bes B., Meunier J.C., Gündüz O., Tóth G., Borsodi A., and Benyhe S. Nociceptin antagonism: probing the receptor by N-acetyl oligopeptides. Regul. Pept. 122 (2004) 199-207
26. Kong H., Raynor K., Yano H., Takeda J., Bell G.I., and Reisine T. Agonists and antagonists bind to different domains of the cloned kappa opioid receptor. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 8042-8046
27. Kramer H.K., and Simon E.J. Role of protein kinase C (PKC) in agonist-induced mu-opioid receptor down-regulation: IPKC translocation to the membrane of SH-SyS5Y neuroblastoma cells is induced by mu agonists. J. Neurochem. 72 (1999) 585-593
28. Lecci A. Peripheral stimulation of NOP receptors inhibits capsaicin-sensitive afferent neurons in humans and non-human primates. Trends Pharm. Sci. 23 (2002) 211
29. Liu M., Huang W.L., Wu D.S., and Priestley J.V. TRPV1, but not P2X (3), requires cholesterol for its function and membrane expression in rat nociceptors. Eur. J. Neurosci. 24 (2006) 1-6
30. Lundbaek J.A., Birn P., Tape S.E., Toombes G.E.S., Sogaard R., Koeppe R.E., Gruner S.M., Hansen A.J., and Andersen O.S. Capsaicin regulates voltage-dependent sodium channels by altering lipid bilayer elasticity. Mol. Pharmacol. 68 (2005) 680-689
31. 2. J. Med. Chem. 38 (1995) 585-586
32. McIntyre P., McLatchie L.M., Chambers A., Phillips E., Clarke M., Savidge J., Toms C., Peacock M., Shah K., Winter J., Weerasakera N., Webb M., Rang H.P., Bevan S., and James I.F. Pharmacological differences between the human and rat vanilloid receptor 1 (VR1). Br. J. Pharmacol. 132 (2001) 1084-1094
33. Meunier J.C. Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor. Eur. J. Pharm. 340 (1997) 1-19
34. Meunier J.C., Mollereau C., Toll L., Suaudeau C., Moisand C., Alvinerie P., Butour J.L., Guillemot J.C., Ferrara P., Monsarrat B., Mazarguil H., Vassart G., Parmentier M., and Costentin J. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377 (1995) 535-632
35. Mezey E., Tóth Z.E., Cortright D.N., Arzubi M.K., Krause J.E., Elde R., Guo A., Blumberg P.M., and Szallasi A. Distribution of mRNA for vanilloid receptor subtype 1 (VR1) and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 3655-3660
36. 5,6-deltorphin II. Neuropeptides 26 (1994) 261-265
37. Numazaki M., Tominaga T., Toyooka H., and Tominaga M. Direct phosphorylation of capsaicin receptor VR1 by protein kinase C epsilon and identification of two target serine residues. J. Biol. Chem. 277 (2002) 13375-13378
38. Olah Z., Karai L., and Iadarola M.J. Protein kinase C alpha is required for vanilloid receptor 1 activation: evidence for the multiple signaling pathways. J. Biol. Chem. 277 (2002) 35752-35759
39. Páldyova E., Bereczki E., Sántha M., Wenger T., Borsodi A., and Benyhe S. Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors. Neurochem. Int. 52 (2008) 321-328
40. Pasternak G.W., Wilson H.A., and Snyder S.H. Differential effects of protein modifying reagents on receptor binding of opiate agonists. Mol. Pharmacol. 11 (1975) 340-351
41. Phillips E., Reeve A., Bevan S., and McIntyre P. Identification of species-specific determinants of the action of the antagonist capsazepine and the agonist PPAHV on TRPV1. J. Biol. Chem. 279 (2004) 17165-17172
42. Plannels-Cases R., Aracil A., Merino J.M., Gallar J., Pérez-Payá E., Belmonte C., González-Ros J.M., and Ferrer-Montiel A.V. Arginine-rich peptides are blockers of VR1 channels with analgesic activity. FEBS Lett. 481 (2000) 131-136
43. Reinscheid R.K., Nothacker H.P., Bourson A., Ardati A., Heningsen R.A., Bunzow J.R., Grandy D.K., Langen H., Monsma Jr. J.F., and Civelli O. Orphanin FQ: a neuropeptide that activates opioidlike G protein-coupled receptors. Science 270 (1995) 792-794
44. Shin E.J., Nah S.Y., Chae J.S., Bing G., Shin S.W., Yen T.P., Baek I.H., Kim W.K., Maurice T., Nabeshima T., and Kim H.C. Dextromethorphan attenuates trimethylin-induced neurotoxicity via sigma1 receptor activation in rats. Neurochem. Int. 50 (2007) 791-799
45. Spetea M., Monory K., Tömböly C., Tóth G., Tzavara E., Benyhe S., Hanoune J., and Borsodi A. In vitro binding and signaling profile of the novel mu-opioid receptor agonist endomorphin-2 in rat brain membranes. Biochem. Biophys. Res. Commun. 250 (1998) 720-725
46. Steenland H.W., Ko S.W., Wu L.J., and Zhuo M. Hot receptors in the brain. Mol. Pain 2 (2006) 34-42
47. Szabó T., Biró T., Gonzalez A.F., Palkovits M., and Blumberg P.M. Pharmacological characterization of vanilloid receptor located in the brain. Mol. Brain Res. 98 (2002) 51-57
48. Tominaga M., Wada M., and Musu M. Potentiation of capsaicin receptor activity by metabotropic ATP receptors as a possible mechanism for ATP-evoked pain and hyperalgesia. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 6951-6956
49. 5-enkephalin-Arg-Phe. Regul. Pept. 122 (2004) 139-146
50. Trevisani M., Smart D., Gunthorpe M.J., Tognetto M., Barbieri M., Campi B., et al. Ethanol elicits and potentiates nociceptor responses via the vanilloid receptor-1. Nat. Neurosci. 5 (2002) 546-551
51. Tseng L.F., Narita M., Suganuma C., Mizoguchi H., Ohsawa M., Nagase H., and Kampine J.P. Differential antinociceptive effect of endomorphin-1 and endomorphin-2 in the mouse. J. Pharm. Exp. Ther. 292 (2000) 576-583
52. Varga A., Bölcskei K., Szo{combining double acute accent}ke E., Almási R., Czéh G., Szolcsányi J., and Petho{combining double acute accent} G. Relative roles of protein kinase A and protein kinase C in modulation of transient receptor potential vanilloid type 1 receptor responsiveness in rat sensory neurons in vitro and peripheral nociceptors in vivo. Neuroscience 140 (2006) 645-657
53. Vetter I., Wise B.D., Montheit G.R., Roberts-Thompson S.J., and Cabot P.J. The mu opioid agonist morphine modulates potentiation of capsaicin-evoked TRPV1 responses through a cyclic AMP-dependent protein kinase A pathway. Mol. Pain 2 (2006) 22
54. Wang H.L., Hsu C.Y., Huang P.C., Kuo Y.L., Li A.H., Yeh T.H., Tso A.S., and Chen Y.L. Heterodimerization of opioid receptor-like 1 and mu-opioid receptors impairs the potency of micro receptor agonist. J. Neurochem. 92 (2005) 1285-1294
55. Wang Y., Kedei N., Wang M., Wang Q.J., Huppler A.R., Toth A., Tran R., and Blumberg P.M. Interaction between protein kinase C mu and the vanilloid receptor type 1. J. Biol. Chem. 279 (2004) 53674-53682
56. Wollemann M., and Benyhe S. Non-opioid actions of opioid peptides. Life Sci. 75 (2004) 257-270
57. Zadina J.E., Hackler L., Ge L.J., and Kastin A.J. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 386 (1997) 499-501
58. Zöllner C., Shaqura M.A., Bopaiah C.P., Mousa S., Stein C., and Schaefer M. Painful inflammation-induced increase in mu-opioid receptor binding and G-protein coupling in primary afferent neurons. Mol. Pharmacol. 64 (2003) 202-210